Semaglutide Pen Injector [Ozempic]
Sponsors
Woman's, University of Maryland, Baltimore, University of Nottingham, General and Teaching Hospital Celje, Qilu Pharmaceutical Co., Ltd.
Conditions
Arterial StiffnessBiomarkersChemotherapeutic ToxicityDiabetes Mellitus, Type 1Diabetes Type 2Endothelial DysfunctionEndothelial Progenitor CellsFMD
Phase 1
Phase 2
Phase 3
Phase 4
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
RecruitingNCT04873050
Start: 2022-01-13End: 2026-03-01Target: 102Updated: 2025-03-13
Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets
NCT05606471
Start: 2021-09-15End: 2023-07-28Target: 45Updated: 2022-11-04
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
CompletedNCT05857085
Start: 2021-12-15End: 2023-04-20Updated: 2023-05-12